Immunology
The Immunology Department at St James’s hospital runs a number of both investigator-led and industry centered drug trials in Immunology.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Pharvaris | A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or | Clinical trial (2021-000227-13) | Pharvaris | Commercial: Industry |
| STOP CSUA | STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema | Observational-non invasive | University | Non-commercial: Academic |
| HyQvia | Non-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQvia | Observational-non invasive (NCT01034969) | Baxalta | Commercial: Industry |
| IOS registry | Icatibant Outcome Survey (IOS) registry protocol | Observational-non invasive (NCT01034969) | Shire | Commercial: Industry |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| HAE Survey | Burden of hereditary angioedema (HAE) and impact on quality of life: A multi-national survey of patients and caregivers | Observational-non invasive | Takeda | Commercial: Industry |
| CDZ OLE | An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02859727)(2016-000468-41) | Novartis | Commercial: Industry |
| CDZ | An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02435173) (2014-003876-22) | Novartis | Commercial: Industry |